Domani Wealth LLC Buys 747 Shares of Johnson & Johnson (JNJ)

Domani Wealth LLC increased its stake in Johnson & Johnson (NYSE:JNJ) by 3.9% in the second quarter, HoldingsChannel reports. The institutional investor owned 19,939 shares of the company’s stock after purchasing an additional 747 shares during the quarter. Johnson & Johnson comprises about 1.1% of Domani Wealth LLC’s holdings, making the stock its 20th largest position. Domani Wealth LLC’s holdings in Johnson & Johnson were worth $2,419,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Raymond James Financial Services Advisors Inc. grew its stake in shares of Johnson & Johnson by 3.5% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 1,123,184 shares of the company’s stock valued at $136,289,000 after buying an additional 38,285 shares in the last quarter. Narwhal Capital Management grew its stake in Johnson & Johnson by 2.5% during the 2nd quarter. Narwhal Capital Management now owns 40,917 shares of the company’s stock valued at $4,965,000 after purchasing an additional 1,010 shares in the last quarter. Cardinal Capital Management grew its stake in Johnson & Johnson by 10.6% during the 2nd quarter. Cardinal Capital Management now owns 101,715 shares of the company’s stock valued at $12,342,000 after purchasing an additional 9,767 shares in the last quarter. Professional Advisory Services Inc. grew its stake in Johnson & Johnson by 18.7% during the 2nd quarter. Professional Advisory Services Inc. now owns 138,922 shares of the company’s stock valued at $16,857,000 after purchasing an additional 21,917 shares in the last quarter. Finally, Wealth Alliance Advisory Group LLC grew its stake in Johnson & Johnson by 9.5% during the 2nd quarter. Wealth Alliance Advisory Group LLC now owns 11,274 shares of the company’s stock valued at $1,368,000 after purchasing an additional 981 shares in the last quarter. Institutional investors and hedge funds own 66.06% of the company’s stock.

A number of equities research analysts have weighed in on the company. Wells Fargo & Co restated an “outperform” rating and set a $160.00 price objective on shares of Johnson & Johnson in a research note on Friday, September 14th. Zacks Investment Research lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Friday, November 16th. HC Wainwright restated a “buy” rating on shares of Johnson & Johnson in a research note on Wednesday, October 17th. Credit Suisse Group set a $149.00 price objective on Johnson & Johnson and gave the company a “buy” rating in a research note on Sunday, October 14th. Finally, Citigroup raised their price objective on Johnson & Johnson from $137.00 to $148.00 and gave the company a “neutral” rating in a research note on Monday, October 22nd. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and ten have assigned a buy rating to the stock. Johnson & Johnson has an average rating of “Hold” and a consensus target price of $143.97.

Shares of JNJ opened at $142.23 on Monday. The company has a market capitalization of $381.59 billion, a PE ratio of 19.48, a PEG ratio of 2.22 and a beta of 0.58. The company has a quick ratio of 1.40, a current ratio of 1.72 and a debt-to-equity ratio of 0.46. Johnson & Johnson has a 52 week low of $118.62 and a 52 week high of $148.75.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 16th. The company reported $2.05 EPS for the quarter, topping the consensus estimate of $2.03 by $0.02. The company had revenue of $20.35 billion during the quarter, compared to analyst estimates of $20.05 billion. Johnson & Johnson had a return on equity of 34.62% and a net margin of 1.89%. The business’s revenue was up 3.6% on a year-over-year basis. During the same quarter last year, the firm earned $1.90 EPS. Equities analysts expect that Johnson & Johnson will post 8.16 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 11th. Stockholders of record on Tuesday, November 27th will be given a $0.90 dividend. The ex-dividend date of this dividend is Monday, November 26th. This represents a $3.60 annualized dividend and a dividend yield of 2.53%. Johnson & Johnson’s payout ratio is 49.32%.

In other news, CAO Ronald A. Kapusta sold 8,441 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, November 8th. The stock was sold at an average price of $145.15, for a total value of $1,225,211.15. Following the completion of the transaction, the chief accounting officer now owns 17,284 shares in the company, valued at approximately $2,508,772.60. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CAO Ronald A. Kapusta sold 7,899 shares of Johnson & Johnson stock in a transaction that occurred on Friday, September 7th. The stock was sold at an average price of $137.18, for a total value of $1,083,584.82. Following the completion of the transaction, the chief accounting officer now owns 25,725 shares of the company’s stock, valued at approximately $3,528,955.50. The disclosure for this sale can be found here. In the last quarter, insiders sold 320,805 shares of company stock valued at $46,684,507. Insiders own 0.22% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Domani Wealth LLC Buys 747 Shares of Johnson & Johnson (JNJ)” was originally posted by WKRB News and is the sole property of of WKRB News. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at https://www.wkrb13.com/2018/11/26/domani-wealth-llc-buys-747-shares-of-johnson-johnson-jnj.html.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: Futures Contract

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply